How does 1951's PE Ratio compare to its peers?

1951 is good value based on its Price-To-Earnings Ratio (24.2x) compared to the peer average (27.8x).

How does 1951's PE Ratio compare vs other companies in the HK Healthcare Industry?

1951 is expensive based on its Price-To-Earnings Ratio (24.2x) compared to the Hong Kong Healthcare industry average (12.9x).

What is 1951's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1951 is expensive based on its Price-To-Earnings Ratio (24.2x) compared to the estimated Fair Price-To-Earnings Ratio (17x).

What is the Fair Price of 1951 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

1951 (HK$2.94) is trading below our estimate of [[fair value]] (HK$8.03)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Jinxin Fertility Group (SHSC:1951) - Stock Price, News & Analysis

1951 Stock Overview

An investment holding company, provides assisted reproductive services (ARS) in China and the United States. More details

1951 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	3/6
Past Performance	4/6
Financial Health	3/6
Dividends	2/6

Rewards

Trading at 63.4% below our estimate of its fair value

Earnings are forecast to grow 19.36% per year

Earnings grew by 101.1% over the past year

Risk Analysis

No risks detected for 1951 from our risk checks.

Jinxin Fertility Group Limited Competitors

Gushengtang Holdings

SEHK:2273

HK$8.2b

Adicon Holdings

SEHK:9860

HK$4.5b

Mega Genomics

SEHK:6667

HK$1.7b

EuroEyes International Eye Clinic

SEHK:1846

HK$1.4b

Price History & Performance

Summary of all time highs, changes and price drops for Jinxin Fertility Group
Historical stock prices
Current Share Price	HK$2.94
52 Week High	HK$4.64
52 Week Low	HK$2.05
Beta	1.36
11 Month Change	-19.45%
3 Month Change	20.99%
1 Year Change	-24.62%
33 Year Change	-74.39%
5 Year Change	-75.29%
Change since IPO	-75.54%

Recent updates

Shareholder Returns

	1951	HK Healthcare	HK Market
7D	-4.5%	-1.5%	-0.6%
1Y	-24.6%	-27.6%	9.6%

Return vs Industry: 1951 exceeded the Hong Kong Healthcare industry which returned -25.8% over the past year.

Return vs Market: 1951 underperformed the Hong Kong Market which returned 10.1% over the past year.

Price Volatility

Is 1951's price volatile compared to industry and market?
1951 volatility
1951 Average Weekly Movement	12.9%
Healthcare Industry Average Movement	7.9%
Market Average Movement	8.9%
10% most volatile stocks in HK Market	19.0%
10% least volatile stocks in HK Market	4.2%

Stable Share Price: 1951 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 1951's weekly volatility (13%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1951	3,779	Yang Dong	www.jxr-fertility.com

Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and the United States. The company primarily offers two treatment solutions, including artificial insemination that is performed with either husband’s sperm or a donor sperm; and IVF technology, whereby fertilization is achieved through conventional in vitro fertilization and embryo transfer or IVF with intracytoplasmic sperm injection. It also provides related services, such as nutrition guidance, Chinese medicine treatment, and psychological counseling to support the ARS.

Jinxin Fertility Group Limited Fundamentals Summary

How do Jinxin Fertility Group's earnings and revenue compare to its market cap?
1951 fundamental statistics
Market cap	HK$8.07b
Earnings (TTM)	HK$333.86m
Revenue (TTM)	HK$3.11b

24.2x

P/E Ratio

2.6x

P/S Ratio

Is 1951 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1951 income statement (TTM)
Revenue	CN¥2.90b
Cost of Revenue	CN¥1.70b
Gross Profit	CN¥1.19b
Other Expenses	CN¥883.30m
Earnings	CN¥310.84m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.11
Gross Margin	41.19%
Net Profit Margin	10.72%
Debt/Equity Ratio	20.9%

How did 1951 perform over the long term?

See historical performance and comparison

Dividends

2.0%

Current Dividend Yield

47%

Payout Ratio

1951 Stock Overview

Rewards

Risk Analysis

Jinxin Fertility Group Limited Competitors

SEHK:2273

HK$8.2b

SEHK:9860

HK$4.5b

SEHK:6667

HK$1.7b

SEHK:1846

HK$1.4b

Price History & Performance

Recent News & Updates

Investor sentiment deteriorates as stock falls 25%

Investor sentiment improves as stock rises 18%

First half 2024 earnings released: EPS: CN¥0.071 (vs CN¥0.084 in 1H 2023)

Jinxin Fertility Group Limited to Report First Half, 2024 Results on Aug 29, 2024

Investor sentiment deteriorates as stock falls 18%

Upcoming dividend of HK$0.059 per share

Recent updates

Investor sentiment deteriorates as stock falls 25%

Investor sentiment improves as stock rises 18%

First half 2024 earnings released: EPS: CN¥0.071 (vs CN¥0.084 in 1H 2023)

Jinxin Fertility Group Limited to Report First Half, 2024 Results on Aug 29, 2024

Investor sentiment deteriorates as stock falls 18%

Upcoming dividend of HK$0.059 per share

Investor sentiment improves as stock rises 15%

Full year 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.049 in FY 2022)

Jinxin Fertility Group Limited, Annual General Meeting, Jun 25, 2024

Full year 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.049 in FY 2022)

Jinxin Fertility Group Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 25 July 2024

Jinxin Fertility Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Investor sentiment improves as stock rises 15%

Non-Executive Director recently bought HK$2.0m worth of stock

Co-CEO & Executive Director recently bought HK$3.6m worth of stock

Investor sentiment deteriorates as stock falls 17%

Jinxin Fertility Group Limited Announces Change of Chief Financial Officer

First half 2023 earnings released: EPS: CN¥0.084 (vs CN¥0.076 in 1H 2022)

Jinxin Fertility Group Limited to Report First Half, 2023 Results on Aug 29, 2023

Co-CEO & Executive Director recently bought HK$7.8m worth of stock

Full year 2022 earnings released: EPS: CN¥0.049 (vs CN¥0.14 in FY 2021)

Investor sentiment deteriorates as stock falls 18%

Now 23% undervalued

Jinxin Fertility Group Limited has completed a Follow-on Equity Offering in the amount of HKD 1.176875 billion.

Investor sentiment improved over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Chairman of the Board recently bought HK$6.5m worth of stock

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

First half 2022 earnings released: EPS: CN¥0.08 (vs CN¥0.063 in 1H 2021)

Jinxin Fertility Group Limited to Report First Half, 2022 Results on Aug 31, 2022

Jinxin Fertility Group Limited Declares Final Dividend for the Year Ended December 31, 2021

Investor sentiment improved over the past week

Upcoming dividend of HK$0.074 per share

Investor sentiment improved over the past week

Jinxin Fertility Group Limited, Annual General Meeting, Jun 28, 2022

CO-CEO & Executive Director recently bought HK$15m worth of stock

Full year 2021 earnings released: EPS: CN¥0.14 (vs CN¥0.10 in FY 2020)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.14 (vs CN¥0.10 in FY 2020)

Jinxin Fertility Group Limited Proposes Final Dividend for the Year Ended December 31, 2021, Payable on July 22, 2022

Investor sentiment deteriorated over the past week

CEO & Executive Director recently bought HK$1.9m worth of stock

CEO & Executive Director recently bought HK$1.0m worth of stock

First half 2021 earnings released: EPS CN¥0.063 (vs CN¥0.048 in 1H 2020)

Independent Non-Executive Director Haw Kuang Lim has left the company

Joint Company Secretary Suet Wing Leung has left the company

CEO & Executive Director recently bought HK$6.2m worth of stock

Full year 2020 earnings released: EPS CN¥0.10 (vs CN¥0.19 in FY 2019)

Chairman of the Board Bin Wang has left the company

Full year 2020 earnings released: EPS CN¥0.10 (vs CN¥0.19 in FY 2019)

Jinxin Fertility Group Limited to Report Q4, 2020 Results on Mar 28, 2021

New 90-day high: HK$19.40

New 90-day high: HK$17.22

New 90-day high: HK$15.80

New 90-day high: HK$15.04

Market bids up stock over the past week

Market bids up stock over the past week